Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Soleno Therapeutics Inc.

Soleno Therapeutics ( ($SLNO) ) has issued an update. On November 11, 2025, Soleno Therapeutics announced that its Board of Directors approved an a...

Soleno Therapeutics Announces $100M Share Buyback Plan

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Soleno Therapeutics yesterday and set a price target of $123.00. Kluska covers ...

Market Cap	$2.54B	P/E Ratio	1127.75
52W High	$90.32	52W Low	$41.50
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	9.2%	52W Position	7.4%
Overall Score	40	Value Score	55
Quality Score	--	Technical Score	25

EPS Current Est	$0.04	EPS Next Est	$3.48
EPS Growth Est	+8600.0%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLNO	$45.11	+0.36%	1.31M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLNO	$45.11	+0.4%	1.31M
3
4
5
6

SLNO

SLNO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Soleno Therapeutics Inc. Data in Excel

Get Soleno Therapeutics Inc. Data in Excel